Drug Profile
SC 410
Alternative Names: SC410Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Sancilio & Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-alcoholic fatty liver disease
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Non-alcoholic fatty liver disease in USA (unspecified route) (Sancilio & Company website, August 2023)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA
- 22 Jan 2016 Sancilio & Company plans to submit an IND application with the US FDA for Non-alcoholic fatty liver disease in late 2016 (Sancilio form S-1; December 2015)